Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.

Journal: The lancet. HIV

Publication Year: 2022

Authors & Co-authors:  Ruel Acosta Liu Gray George Montañez Popson Buchanan Bartlett Dayton